Cargando…
Global proteomic characterization of microdissected estrogen receptor positive breast tumors
We here describe two proteomic datasets deposited in ProteomeXchange via PRIDE partner repository [1] with dataset identifiers PXD000484 (defined as “training”) and PXD000485 (defined as “test”) that have been used for the development of a tamoxifen outcome predictive signature [2]. Both datasets co...
Autores principales: | De Marchi, Tommaso, Liu, Ning Qing, Sting, Christoph, Smid, Marcel, Tjoa, Mila, Braakman, René B.H., Luider, Theo M., Foekens, John A., Martens, John W.M., Umar, Arzu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773412/ https://www.ncbi.nlm.nih.gov/pubmed/26958599 http://dx.doi.org/10.1016/j.dib.2015.09.034 |
Ejemplares similares
-
Proteomics Pipeline for Biomarker Discovery of Laser Capture Microdissected Breast Cancer Tissue
por: Liu, Ning Qing, et al.
Publicado: (2012) -
Proteomic characterization of microdissected breast tissue environment provides a protein‐level overview of malignant transformation
por: Braakman, René B. H., et al.
Publicado: (2017) -
4‐protein signature predicting tamoxifen treatment outcome in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015) -
Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer
por: Liu, Ning Qing, et al.
Publicado: (2014) -
Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015)